Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RACING: Ramucirumab + Nab-paclitaxel + Gemcitabine in Pancreatic Cancer
NCT03745430Phase 2Completed
- Sponsor
- HeCOG
- Start
- Jan 2019
- Primary completion
- Jun 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab in pancreatic adenocarcinoma (PDAC), sponsored by HeCOG. Primary endpoints: Recommended Dose and Objective Response Rate up to 33 months. Started Jan 2019; status: completed.
02
Drugs
ramucirumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03745430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03745430.